Journal of Drug Delivery Science and Technology中科院3区，影响因子4.9

　　今天介绍生物医药方向的3区期刊，Journal of Drug Delivery Science and Technology是中科院3区刊物，影响因子4.9，期刊旨在推动制药和药物递送技术的创新发展，为临床用药提供科学依据，下面展开具体的介绍。

　　1、期刊基本信息

　　期刊名称：Journal of Drug Delivery Science and Technology

　　创刊时间：2004

　　影响因子：4.9

　　实时影响因子：4.806

　　五年影响因子：5.2

　　中科院分区：3区

　　JCR分区：1区

　　自引率：8.2%

　　年发文量：1084

　　发行频率：双月刊

　　2、期刊基本指标分析

　　(1)影响因子：Journal of Drug Delivery Science and Technology影响因子近2年较为稳定，最新影响因子4.9，实时影响因子4.806，5年影响因子5.2。

　　(2)分区：期刊位于中科院大类-医学3区，在小类-药学中位于3区，投稿难度一般。JCR数据显示，期刊长期在Q1区，投稿有一定门槛。

　　(3)自引率和引用关系：期刊自引率8.2%，没有预警风险，还是比较安全的刊物。

　　3、期刊收稿范围和稿件类型

　　收稿范围：主要接收所有药物剂型研究，包括控释、生物利用度和药物吸收、纳米药物、基因递送、组织工程。

　　稿件类型：原始研究、综述、短通讯。

　　4、年发文量及国人占比

　　年发文量逐年上升，最近一年发文量在1084，预计可能进一步上升，录用机会大了很多。从数据库信息显示：埃及知识库、德黑兰医科大学和印度国家医药教育与研究所的发文量前三。近三年，中国地区的发文量第2，对国人友好。

　　5、审稿周期

　　Journal of Drug Delivery Science and Technology官网显示，初审只需8天，审稿87天，提交到接受需要115天。近期出版的3篇文章，最快2个月录用，最慢6个月。

　　具体时间如下：

　　第一篇：12月17日提交，6月1日接受。

　　第二篇：2月18日提交，5月28日接受。

　　第三篇：3月21日提交，5月31日接受。

　　6、投稿经验分享

　　有4名学者分享了相关经验，具体如下：

　　学者1：审稿比较慢，4个月的等待太漫长了。但结果是好的。

　　学者2：这个杂志处理稿件的效率实在很低，underview时间很长。

　　学者3：2个审稿专家，审稿周期近两月，审稿意见共10余条，大多都不难回复。

　　学者4：审稿速度太慢，太浪费时间，审稿5个月却拒稿了。

　　学者5：2个审稿人，审稿很快，2-3个周就有审稿意见，一次大修一次小修，小修后第二天就接受了，编辑很负责，很好得杂志。

　　7、期刊近期接收的文章如下

　　1)Bardoxolone methyl improves survival and reduces clinical measures of kidney injury in tumor-bearing mice treated with cisplatin

　　Acute kidney injury (AKI) occurs in approximately one-third of patients treated with cisplatin and there is an outstanding need for mitigation strategies to decrease the frequency and severity of cisplatin-ind...

　　Authors:Lauren E. Thompson, Stacey M. Tuey, Paola Garcia Gonzalez, Carly S. Chesterman, Courtney D. McGinnis, M. Scott Lucia, Lauren M. Aleksunes, Charles L. Edelstein and Melanie S. Joy

　　Citation:AAPS Open 2025 11:6

　　Content type:Research

　　Published on: 3 March 2025

　　2)Atezolizumab neutralizing assay development: a novel way of evaluating assay cutpoint after sample pretreatment

　　Atezolizumab, a biotherapeutic monoclonal antibody directed against PD-L1, has been shown to be efficacious in multiple oncology indications. In clinical trials, a subset of patients developed anti-atezolizuma...

　　Authors:Rachel Melendez, Jane Ruppel, Cecilia Leddy, Jenny Yang, Ann Brady, Yenny Webb-Vargas, Jochen Brumm, Lynn Kamen and Yuan Song

　　Citation:AAPS Open 2025 11:3

　　Content type:Research

　　Published on: 3 February 2025

　　3)A digital platform for automated analysis of 1H NMR data: prototype framework of digital reference standard

　　This study introduces an innovative approach to automatically analyzing 1H nuclear magnetic resonance (NMR) data, integrating a quantum mechanical spectral analysis (QMSA) to enhance efficiency over manual data a...

　　Authors:Sunil Babu Paudel, Joo-Won Nam, Gonzalo R. Malca Garcia, Ben Shapiro, Pekka Laatikainen and Yang Liu

　　Citation:AAPS Open 2025 11:2

　　Content type:Research

　　Published on: 20 January 2025

　　4)Advancements in regulatory agility, regional collaboration, and digital transformation: insights from the Asia Partnership Conference of Pharmaceutical Associations (APAC)

　　The Asia Partnership Conference of Pharmaceutical Associations (APAC) examines recent developments in regulatory practices across Asia, focusing on regulatory agility, regional collaboration, and digital trans...

　　Authors:Sannie Siaw Foong Chong, Stephanie Hui Min Ong, Siew Mei Long, Masaaki Kanno, Usanee Harnpramukkul, Kum Cheun Wong, Asawari Sathaye, Mamta Singh, Manish Paliwal, Huyen Do, Helene Sou and Richard Simon R. Binos

　　Citation:AAPS Open 2024 10:14

　　Content type:Research

　　Published on: 16 December 2024

　　5)Metallic nanoparticles in malaria treatment: advances in therapeutics, diagnostics, and future prospects

　　Malaria remains one of the causes of extreme mortality in southern Africa and Southeast Asia. Despite extreme efforts to control and eliminate malaria, the appearance of drug-resistant parasites and their spre...

　　Authors:Shweta Sinha, Rakesh Sehgal and Bikash Medhi

　　Citation:AAPS Open 2024 10:13

　　Content type:Review

　　Published on: 2 December 2024

　　6)Poloxamers anchored with TAT enhance blood–brain barrier penetration of carbamazepine for the treatment of epilepsy: an in vivo study

　　Carbamazepine is a pharmacological medication commonly prescribed to treat epilepsy. Dose adjustments, poor bioavailability, and prolonged side effects present significant challenges associated with its use. P...

　　Authors:Farnaz Sotoudegan, Mohsen Amini, Mohammad Sharifzadeh, Nasrin Samadi and Farzaneh Sotoudegan

　　Citation:AAPS Open 2024 10:12

　　Content type:Research

　　Published on: 4 November 2024

　　7)Pharmacokinetic interaction between single and multiple doses of darunavir, in combination with cobicistat or ritonavir, and single-dose dabigatran etexilate in healthy adults

　　Darunavir (DRV) is a P-glycoprotein (P-gp) inhibitor. Dabigatran etexilate, prodrug of the anticoagulant dabigatran, is a P-gp probe substrate. This study evaluated the effect of single and multiple doses of D...

　　Authors:Sandy Van Hemelryck, Erika Van Landuyt, Jay Ariyawansa, Martyn Palmer, Martine J. C. Kothe and Caroline Pollefliet

　　Citation:AAPS Open 2024 10:10

　　Content type:Research

　　Published on: 14 October 2024

　　8)Pre-analytical stability of ocrelizumab in serum after delayed centrifugation of whole blood

　　Authors:Jeongsup Shim, Montserrat Carrasco-Triguero and Saloumeh K. Fischer

　　Citation:AAPS Open 2024 10:11

　　Content type:Rapid communication

　　Published on: 16 September 2024

　　总结来看：Journal of Drug Delivery Science and Technology长期位于中科院3区，发展较好，但是审稿速度一般，大概3-4月左右，对于从事创新研究，如纳米技术、新型制剂开发等前沿方向的学者，可以积极投稿。